Development of Auto Antigen-specific Regulatory T Cells for Diabetes Immunotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
CD4+ regulatory T cells (Tregs) are essential for normal immune surveillance, and their dysfunction can lead to the development of autoimmune diseases, such as type-1 diabetes (T1D). T1D is a T cell-mediated autoimmune disease characterized by islet b cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. Tregs play a critical role in the development of T1D and participate in peripheral tolerance. Pluripotent stem cells (PSCs) can be utilized to obtain a renewable source of healthy Tregs to treat T1D as they have the ability to produce almost all cell types in the body, including Tregs. However, the right conditions for the development of antigen (Ag)-specific Tregs from PSCs (i.e. , PSC-Tregs) remain undefined, especially molecular mechanisms that direct differentiation of such Tregs. Auto Ag-specific PSC-Tregs can be programmed to be tissue-associated and infiltrate to local inflamed tissue (e.g. , islets) to suppress autoimmune responses after adoptive transfer, thereby avoiding potential overall immunosuppression from non-specific Tregs. Developing auto Ag-specific PSC-Tregs can reduce overall immunosuppression after adoptive transfer by accumulating inflamed islets, which drives forward the use of therapeutic PSC-Tregs for cell-based therapies in T1D.
Abstract
CD4+ regulatory T cells (Tregs) are essential for normal immune surveillance, and their dysfunction can lead to the development of autoimmune diseases, such as type-1 diabetes (T1D). T1D is a T cell-mediated autoimmune disease characterized by islet b cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. Tregs play a critical role in the development of T1D and participate in peripheral tolerance. Pluripotent stem cells (PSCs) can be utilized to obtain a renewable source of healthy Tregs to treat T1D as they have the ability to produce almost all cell types in the body, including Tregs. However, the right conditions for the development of antigen (Ag)-specific Tregs from PSCs (i.e. , PSC-Tregs) remain undefined, especially molecular mechanisms that direct differentiation of such Tregs. Auto Ag-specific PSC-Tregs can be programmed to be tissue-associated and infiltrate to local inflamed tissue (e.g. , islets) to suppress autoimmune responses after adoptive transfer, thereby avoiding potential overall immunosuppression from non-specific Tregs. Developing auto Ag-specific PSC-Tregs can reduce overall immunosuppression after adoptive transfer by accumulating inflamed islets, which drives forward the use of therapeutic PSC-Tregs for cell-based therapies in T1D.
참고문헌 (36)
- Bluestone, J. A, "Type 1diabetes immunotherapy using polyclonal regulatory T cells", Sci. Transl. Med, 7, pp.315ra189~ (2015)
- Mahne, A. E, "Therapeutic regulatory T cells subvert effector T cell function in inflamed islets to halt autoimmune diabetes", J. Immunol, 194, pp.3147~3155 (2015)
- Hossain, D. M, "FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells", Immunity, 39, pp.1057~1069 (2013)
- Aschenbrenner, K, "Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells", Nat. Immunol, 8, pp.351~358 (2007)
- Haque, R, "FoxP3and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development", Arthritis Res. Ther, 12, pp.R66~ (2010)
- van Herwijnen, M. J, "Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis", Proc. Natl. Acad. Sci. U. S. A, 109, pp.14134~14139 (2012)
- Wright, G. P, "Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis", Proc. Natl. Acad. Sci. U. S. A, 106, pp.19078~19083 (2009)
- Sela, U, "Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice", J. Exp. Med, 208, pp.2489~2496 (2011)
- Bacher, P, "Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi", Mucosal Immunol, 7, pp.916~928 (2014)
- Nguyen, T. L, "Antigen-specific TGF-beta-induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity", J. Immunol, 187, pp.1745~1753 (2011)
- Haque, M, "Stem cell-derived tissue-associated regulatory T cells ameliorate the development of autoimmunity", Sci. Rep, 6, pp.20588~ (2016)
- Van Belle, T. L, "NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes", J. Autoimmun, 40, pp.66~73 (2013)
- Takiishi, T, "Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice", J. Clin. Invest, 122, pp.1717~1725 (2012)
- Vogtenhuber, C, "Outgrowth of CD4low", negCD25+ T cells with suppressor function in CD4+CD25+ T cell cultures upon polyclonal stimulation ex vivo, 2008, pp.181, 8767~8775
- Sharma, M. D, "An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos", Immunity, 38, pp.998~1012 (2013)
- Perro, M, "Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer", Gene Ther, 17, pp.721~732 (2010)
- Porter, D. L, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", N. Engl. J. Med, 365, pp.725~733 (2011)
- Bendle, G. M, "Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy", Nat. Med, 16, pp.565~570 (2010)
- Gratz, I. K, "Cutting Edge:memory regulatory t cells require IL-7 and not IL-2 for their maintenance in peripheral tissues", J. Immunol, 190, pp.4483~4487 (2013)
- Kuball, J, "Facilitating matched pairing and expression of TCR chains introduced into human T cells", Blood, 109, pp.2331~2338 (2007)
- van Loenen, M. M, "Mixed T cell receptor dimers harbor potentially harmful neoreactivity", Proc. Natl. Acad. Sci. U. S. A, 107, pp.10972~10977 (2010)
- Kim, Y. C, "Engineered antigen-specific human regulatory T cells:immunosuppression of FVIII-specific T- and B-cell responses", Blood, 125, pp.1107~1115 (2015)
- Haque, R, "Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity", J. Immunol, 189, pp.1228~1236 (2012)
- Kim, J. B, "Oct4-induced pluripotency in adult neural stem cells", Cell, 136, pp.411~419 (2009)
- Zhao, T, "Immunogenicity of induced pluripotent stem cells", Nature, 474, pp.212~215 (2011)
- Lei, F, "In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance", Cancer Res, 71, pp.4742~4747 (2011)
- Haque, M, "Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells", Cell Transplant, 25, pp.811~827 (2016)
- Themeli, M, "Generation of tumortargeted human T lymphocytes from induced pluripotent stem cells for cancer therapy", Nat. Biotechnol, 31, pp.928~933 (2013)
- Vizcardo, R, "Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells", Cell Stem Cell, 12, pp.31~36 (2013)
- Saito, H, "Adoptive transfer of CD8+ T cells generated from induced pluripotent stem cells triggers regressions of large tumors along with immunological memory", Cancer Res, 76, pp.3473~3483 (2016)
- Dervovic, D. D, "Cellular and molecular requirements for the selection of in vitro-generated CD8 T cells reveal a role for Notch", J. Immunol, 191, pp.1704~1715 (2013)
- Wendorff, A. A, "Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation", Immunity, 33, pp.671~684 (2010)
- Guo, Y, "Core binding factors are necessary for natural killer cell development and cooperate with Notch signaling during T-cell specification", Blood, 112, pp.480~492 (2008)
- Lei, F, "Transgenic expression of survivin compensates for OX40-deficiency in driving Th2development and allergic inflammation", Eur. J. Immunol, 43, pp.1914~1924 (2013)
- Y Cheng, "eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis", Oncogene, 35(49), pp.6293~6308 (2016), Springer Nature[DOI]
- Di, S. A, "Inducible apoptosis as a safety switch for adoptive cell therapy", N. Engl. J. Med, 365, pp.1673~1683 (2011)